Qlucore receives first commercial order for new solution

09 September 2021 - 14:30

Neoscreen Medical Ltd will use Qlucore’s new precision-based leukemia diagnostics.

The Swedish software company Qlucore has signed an agreement with Neoscreen Medical Ltd., Qlucore’s first contract for its new solutions for precisions diagnostics. Neoscreen will use Qlucore’s highly configurable for RNA-seq based diagnostics software to facilitate and speed up decision support and diagnostics for acute lymphoblastic leukemia (ALL).

Cancer diagnostics are changing rapidly and Qlucore is at the forefront of this development. The first application area for Qlucore’s diagnostics platform is RNA-seq based cancer diagnostics in leukemia.

Carl-Johan Ivarsson, CEO at Qlucore, comments: "Our solutions makes it easier and speeds up cancer diagnostics. Detection and analysis of gene fusions and expression-based classification is moving quickly from research to clinical use. We are proud to support Neoscreen and help them provide their clients’ diagnostics support with fast and visual results."

Transcriptional profiling of cancer has a great clinical utility to significantly improve clinical diagnostics. Addition of RNA sequencing in the diagnostics workup of leukemia (ALL) is becoming increasingly important for clinical decision-making as it allows unbiased detection of gene fusions and subtype classification based on gene expression signatures not accessible by DNA-based gene panel analysis. Gene fusions are important diagnostic markers according to the current guidelines for leukemia (ALL and AML).

Yannis L. Loukas, Neoscreen Scientific Director and Assoc. Professor at Athens School of Pharmacy, Greece, comments: “We are delighted to broaden our service with this new RNA-seq based cancer diagnostics platform from Qlucore. This will enable us to provide genetic subtype classifications of leukemia and unbiased gene fusion analysis to our clients.”

Qlucore’s solutions are currently available for research use only and work is ongoing to obtain a CE mark. The company’s advanced software enables faster and better precision-based cancer diagnostics where the AI-powered machine learning based components makes it possible to subtype patients. Qlucore’s software solutions are unique and with combined advanced visualization, mathematics and biology, makes it accessible to the user. Qlucore is well established with leading academic institutions and pharmaceutical companies.

About Neoscreen Medical Ltd.
Neoscreen Medical Ltd. was founded in 2007 as a Laboratory of Neonatal and Prenatal Testing. It started its activities with the expanded control of newborns in order to sort out suspicious cases concerning 60 metabolic diseases. So far we have carried out about 80,000 testings. We then expanded our genetic testing activities to detect germline mutations, having performed more than 70,000 genetic testing (September 2020). Our services range from the detection of a specific mutation to the analysis of the entire genome. Neoscreen is an ISO 15189 accredited laboratory and performs molecular diagnostic testing including molecular onclology tests.

Provided by: MFN
Nasdaq First North GM (Sweden)
Qlucore AB
Qlucore makes it easier to analyze the huge amounts of complex data that are generated by innovations in the fields of genetics and proteomics. It is done by providing powerful visualization-based bioinformatics data analysis tools for research and precision diagnostics....
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More